← Back to screener

Beta Bionics, Inc. BBNX

Rank #2028 · Nasdaq · $0.7B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
35.9
P/E
-13.6
P/B
-3.67
ROE
27.0%
Op. Margin
-69.5%
Debt Ratio
-36%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -13.6x, P/B -3.67x. Ranks in the top 92% of the universe.

Profitability ★★☆☆☆
Average

ROE 27.0%. Ranks in the top 52% of the universe.

Safety ★★★★★
Excellent

Debt ratio -36%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 442.9% year over year. Ranks in the top 1% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024$0.0B$-0.0B$-0.0B$-0.2B-298.9-30
2025$0.1B$-0.0B$-0.1B$-0.2B-69.5-36

← See the full screener